Almirall Signs a Research Collaboration with HitGen for its DNA-Encoded Technology

 Almirall Signs a Research Collaboration with HitGen for its DNA-Encoded Technology

Almirall Signs a Research Collaboration with HitGen for its DNA-Encoded Technology

Shots:

  • HitGen to receive upfront & milestones from Almirall to develop novel small molecules for Almirall’s target
  • The focus of the collaboration is to utilize HitGen’s technology based on DNA-encoded library design, synthesis and screening, in identifying small molecules for the treatment of atopic dermatitis
  • HitGen’s DELs is a drug discovery platform including 400B macrocyclic compounds developing biological targets. The company has also collaborated with other companies & foundations in North America, Europe, Asia & Africa to discover therapies & agrochemical solutions in multiple therapy areas

Click here to read full press release/ article | Ref: HitGen | Image: Business Wire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post